Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development
Kai Song, … , Yibin Kang, Hong Chen
Kai Song, … , Yibin Kang, Hong Chen
Published September 22, 2020
Citation Information: J Clin Invest. 2021;131(1):e129374. https://doi.org/10.1172/JCI129374.
View: Text | PDF
Research Article Cell biology Oncology Article has an altmetric score of 3

Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development

  • Text
  • PDF
Abstract

Estrogen receptor–negative (ER-negative) breast cancer is thought to be more malignant and devastating than ER-positive breast cancer. ER-negative breast cancer exhibits elevated NF-κB activity, but how this abnormally high NF-κB activity is maintained is poorly understood. The importance of linear ubiquitination, which is generated by the linear ubiquitin chain assembly complex (LUBAC), is increasingly appreciated in NF-κB signaling, which regulates cell activation and death. Here, we showed that epsin proteins, a family of ubiquitin-binding endocytic adaptors, interacted with LUBAC via its ubiquitin-interacting motif and bound LUBAC’s bona fide substrate NEMO via its N-terminal homolog (ENTH) domain. Furthermore, epsins promoted NF-κB essential modulator (NEMO) linear ubiquitination and served as scaffolds for recruiting other components of the IκB kinase (IKK) complex, resulting in the heightened IKK activation and sustained NF-κB signaling essential for the development of ER-negative breast cancer. Heightened epsin levels in ER-negative human breast cancer are associated with poor relapse-free survival. We showed that transgenic and pharmacological approaches eliminating epsins potently impeded breast cancer development in both spontaneous and patient-derived xenograft breast cancer mouse models. Our findings established the pivotal role epsins played in promoting breast cancer. Thus, targeting epsins may represent a strategy to restrain NF-κB signaling and provide an important perspective into ER-negative breast cancer treatment.

Authors

Kai Song, Xiaofeng Cai, Yunzhou Dong, Hao Wu, Yong Wei, Uma T. Shankavaram, Kui Cui, Yang Lee, Bo Zhu, Sudarshan Bhattacharjee, Beibei Wang, Kun Zhang, Aiyun Wen, Scott Wong, Lili Yu, Lijun Xia, Alana L. Welm, Diane R. Bielenberg, Kevin A. Camphausen, Yibin Kang, Hong Chen

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2009 Total
Citations: 4 1 4 5 3 1 1 19
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (19)

Title and authors Publication Year
Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities
Awan AB, Osman MJ, Khan OM
Cells 2025
Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
Su H, Shen J, Gao C, Zhao Y, Deng W, Qin B, Zhang X, Lai J, Wang Q, Dou J, Guo M
Cell & Bioscience 2025
NEMO Family of Proteins as Polyubiquitin Receptors: Illustrating Non-Degradative Polyubiquitination’s Roles in Health and Disease
Wu CJ
Cells 2025
Tob negatively regulates NF-κB activation in breast cancer through its association with the TNF receptor complex.
Tokumasu M, Sato A, Ito-Kureha T, Yamamoto M, Ohmine N, Semba K, Inoue JI, Yamamoto T
Cancer gene therapy 2025
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y, Lu B, Fan Y, Liu Z, Chen X, Jia X, Dong Z, Liu K
Molecular Cancer 2024
Repositioning linifanib as a potent anti-necroptosis agent for sepsis
Yu L, Yang K, He X, Li M, Gao L, Zha Y
Cell Death Discovery 2023
Targeting Epsins to Inhibit FGF Signaling while Potentiating TGF-β Signaling Constrains Endothelial-to-Mesenchymal-Transition in Atherosclerosis
Dong Y, Wang B, Du M, Zhu B, Cui K, Li K, Yuan K, Cowan DB, Bhattacharjee S, Wong S, Shi J, Wang DZ, Chen K, Bischoff J, Linton MF, Chen H
Circulation 2023
Peptidase inhibitor (PI16) impairs bladder cancer metastasis by inhibiting NF-κB activation via disrupting multiple-site ubiquitination of NEMO
Kuang X, Zhang Z, Li D, Bao W, Pan J, Zhou P, Chen H, Gao Z, Xie X, Yang C, Zhu G, Zhou Z, Tang R, Feng Z, Zhou L, Feng X, Wang L, Yang J, Jiang L
Cellular & Molecular Biology Letters 2023
Mechanisms underlying linear ubiquitination and implications in tumorigenesis and drug discovery.
Li J, Liu S, Li S
Cell communication and signaling : CCS 2023
Tumor-intrinsic and immune modulatory roles of receptor-interacting protein kinases
A Rucker, F Chan
Trends in Biochemical Sciences 2022
Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment (Review)
Zhang X, Meng T, Cui S, Liu D, Pang Q, Wang P
International journal of oncology 2022
Emerging Roles of Non-proteolytic Ubiquitination in Tumorigenesis
Yin X, Liu Q, Liu F, Tian X, Yan T, Han J, Jiang S
Frontiers in Cell and Developmental Biology 2022
Interferon-alpha responsible EPN3 regulates hepatitis B virus replication
Li X, Wang Z, Zhou W, Fu X, Zhang Y, Sun Y, Yang B, Bai Y, Dai C, Xu X, Cui F, Zhao Y, Zhang Y, Wang B, Li Y, Muramatsu M, Wakae K, Liu G
Frontiers in Medicine 2022
The resurrection of RIP kinase 1 as an early cell death checkpoint regulator—a potential target for therapy in the necroptosis era
Ju E, Park KA, Shen HM, Hur GM
Experimental & molecular medicine 2022
Gene Signatures Induced by Ionizing Radiation as Prognostic Tools in an In Vitro Experimental Breast Cancer Model
GM Calaf, LA Crispin, D Roy, F Aguayo, JP Muñoz, TC Bleak
Cancers 2021
Met1-linked ubiquitin signalling in health and disease: inflammation, immunity, cancer, and beyond
AS Jahan, CR Elbæk, RB Damgaard
Cell Death and Differentiation 2021
Epsin 3 potentiates the NF‑κB signaling pathway to regulate apoptosis in breast cancer
Q Wu, Q Li, W Zhu, X Zhang, H Li
Molecular medicine reports 2021
Endocytic Adaptors in Cardiovascular Disease
K Cui, Y Dong, B Wang, DB Cowan, SL Chan, J Shyy, H Chen
Frontiers in Cell and Developmental Biology 2020
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 4 X users
16 readers on Mendeley
See more details